1

Identity

Pfizer, S.L.U.

B28089225

€730M

Amount awarded, solo awards 2016–2026

Amount awarded by year
YearAmountDistribution
2026*€156.0M
2025€169.3M
2024€92.8M
+ regional platforms
2023€72.9M
2022€57.9M
2021€64.8M
2020€45.7M
2019€34.8M
2018€15.6M
2017€18.1M
2016€2.7M
*2026: data to 31 October · 164 contracts in 2026 · Since 2024 this also includes data from regional platforms. · Solo awards, excluding JVs · Framework agreements at €0 · €M
1,332
Contracts (lots)
across 1,060 tenders
68
Buyers
87%
Single bidder
13
Awards in UTEs
not in the total

In figures

Volume

Between 2016 and 2026 it won 1,332 contracts worth €730M on its own, with 68 buyers. Its 13 joint-venture (UTE) contracts are shown separately.

Price

In 2024–2026 its median discount was 30.9%; the middle half of its discounts between 28.7% and 38.3% (7 comparable awards).

Competition

Since 2024, 85% of its comparable value was won with a discount and against other bidders. It was the only bidder in 87% of its contracts (2016–2026).

Renewals

99 contracts (€63.0M) come up for tender again in the next 24 months.

A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Pfizer, S.L.U.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Pfizer, S.L.U.'s share.

Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage

2

Its discounts

The discount at which it wins contested contracts, year by year.

2024–2026: median 30.9% · middle half between 28.7% and 38.3% · 7 awards

2019–2026: median 28.9% · middle half between 8.8% and 39.0% · 23 awards

Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →

Where it wins, and at what discount

In the report · these discounts, one by one

Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.

By sector

Productos farmacéuticos

CPV 336

732 contracts · €417M

Request the report →

Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.

Distribution of its discounts
How far winning bids are below the published contract value — its contested awards, the same ones the chart shows.
Median discount: 30.9% below the published contract value · 7 awards (2024–2026).
Discount
Awards
15–30 %
3
30 %+
4

6 awards at the tender price, left out of the discounts.

3

How it wins

Whether it wins with or without competition.

Competition and pricing

85% of the comparable value since 2024 (€12.4M of €14.5M) was won with a discount and against other bidders. €1.30M (9%) was awarded at the tender price and without other bidders.

With a discount
6%
single bidder · 11 · €798k
85%
multiple bidders · 7 · €12.4M
At the tender price
9%
single bidder · 19 · €1.30M
0%
multiple bidders · 0

Comparable: 37 awards with a published budget and bidder count (€14.5M of €418M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.

Award procedure

Between 2016 and 2026, 70.0% of the value was awarded through negotiated without publicity procedure (42.9% of contracts); followed by Based on a framework agreement (10.9%) and Open (8.8%).

Based on a framework agreement · 10.9%
Negotiated without publicity · 70.0%
Open
Negotiated with publicity
Based on a framework agreement
Negotiated without publicity
Other
4

Upcoming tenders and main buyers

When its contracts come back and who it sells to.

When its contracts come back

In the next 24 months 99 of its contracts come up for tender again, worth €63.0M.

Expected endBuyerValue
2026Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria€54.1k
2026Gerencia de Servicio Sanitarios de Fuerteventura€46.2k
2026Gerencia de Servicio Sanitarios de Fuerteventura€17.7k
2026Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad—
2026Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad—

and 94 more in the next 24 months · the report includes them all

Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.

Who they sell to
BuyerContractsValue, €Period
OSAKIDETZA - Servicio Vasco de Salud -Director General2398 M2024–2026
Servicio Andaluz de Salud9885 M2024–2026
Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín51266 M2018–2026
Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad7165 M2020–2026
Departament de Salut2856 M2022–2026

and 63 more buyers

Sector activity
Top CPV codes — the EU classification system that identifies the type of works, services or supplies covered by each contract.

Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,311 contracts).

Medical & pharmaceuticals
100.0%1311 contracts
5

Recent awards

The evidence behind every insight in the report.

Latest 5 completed contracts (of 564)
Contracts whose expected completion date has passed.
DateContractBuyerBiddersValue
03/07/2026Suministro De Medicamentos De Uso Humano Tipo Ii (Exclusivos), Con Destino Al Servicio De Farmacia …Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria2€36.3k
03/07/2026Suministro de medicamentos de uso humano exclusivos, con destino al servicio de farmacia del hospit…Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria5€12.8k
08/06/2026cpca 1º cbam pfizer, s.l. exp. 578/2025 suministro medicamento exclusivos cca: +6.i+e0q8j, am contr…Servicio Andaluz de Salud1€335k
27/04/2026Contrato basado en el AM INGESA 2025/034, para el suministro respetuoso con el medio ambiente de me…Servicio Cántabro de Salud1€5.09k
13/03/2026Suministro Farmacéutico de los Principios Activos Adalimumab (20,40 y 80), Trastuzumab (150 y 420 )…Gerencia de Servicio Sanitarios de Fuerteventura1€17.7k
Full report on Pfizer, S.L.U.
Includes: its discount by buyer and sector · winning discounts by buyer and year · how it wins with each buyer · contract renewal calendar. The complete register of its awards in the last three full calendar years and the current year to date, in Excel.
€50 + VAT · VAT is calculated at payment according to your country. You will receive it in PDF and Excel by email within one working day. Every report is reviewed by a person before it is sent to you.
Order the report